21 – 30 of 30
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- 3
- next »
- 2012
-
Mark
Barnet i sjukvården
2012) p.113-124(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2011
-
Mark
Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
(
- Contribution to journal › Article
- 2009
-
Mark
Individualized 6-Mercaptopurine Increments During Consolidation Treatment Of Lower Risk Childhood All
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia
(
- Contribution to journal › Article
-
Mark
Exit of pediatric pre-B acute lymphoblastic leukaemia cells from the bone marrow to the peripheral blood is not associated with cell maturation or alterations in gene expression.
(
- Contribution to journal › Article
-
Mark
Mycket svåra beslut
2008) p.231-248(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2005
-
Mark
Differential regulation of granulopoiesis by the basic helix-loop-helix transcriptional inhibitors Id1 and Id2
(
- Contribution to journal › Article
-
Mark
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.
(
- Contribution to journal › Article
- 2003
-
Mark
Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents
(
- Contribution to journal › Article
- 2002
-
Mark
Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: Multi-institutional collaborative study
(
- Contribution to journal › Article
- « previous
- 1
- 2
- 3
- next »